Provided by Tiger Fintech (Singapore) Pte. Ltd.

ResMed

282.03
-3.1450-1.10%
Volume:367.17K
Turnover:103.43M
Market Cap:41.29B
PE:29.66
High:285.09
Open:284.73
Low:279.63
Close:285.17
52wk High:293.81
52wk Low:199.92
Shares:146.41M
Float Shares:145.51M
Volume Ratio:0.66
T/O Rate:0.25%
Dividend:2.12
Dividend Rate:0.75%
EPS(TTM):9.51
EPS(LYR):9.55
ROE:25.86%
ROA:14.02%
PB:6.92
PE(LYR):29.54

Loading ...

ResMed Q4 Adj. EPS $2.55 Beats $2.46 Estimate, Sales $1.348B Beat $1.321B Estimate

Benzinga
·
Aug 01

Resmed Q4 Adjusted Gross Margin 61.4%

THOMSON REUTERS
·
Aug 01

Resmed Q4 Adjusted EPS USD 2.55 VS. Ibes Estimate USD 2.48

THOMSON REUTERS
·
Aug 01

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

THOMSON REUTERS
·
Aug 01

ResMed Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
Jul 30

Calculating The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

Simply Wall St.
·
Jul 29

Don't Need Your Required Minimum Distribution (RMD) Right Now? What Can You Do With the Cash Influx?

Motley Fool
·
Jul 27

DIARY-Australia, New Zealand corporate earnings week ahead

Reuters
·
Jul 26

Are You Making These 4 Common Required Minimum Distribution (RMD) Mistakes?

Motley Fool
·
Jul 24

ResMed Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
Jul 23

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Receives a Buy from Jarden

TIPRANKS
·
Jul 22

ResMed Inc. Stock Rises Monday, Outperforms Market

Dow Jones
·
Jul 22

Is Taking Your Required Minimum Distribution (RMD) in December a Smart Move?

Motley Fool
·
Jul 21

What Are 7 Strategic Ways for Retirees to Use Their Required Minimum Distribution (RMD)?

Motley Fool
·
Jul 19

Jarden Adjusts ResMed's Price Target to AU$40.55 from AU$40.54, Keeps at Overweight

MT Newswires Live
·
Jul 18

ResMed Bulls See Potential for 4Q Margin Beat -- Market Talk

Dow Jones
·
Jul 18

This ResMed Insider Reduced Their Stake By 72%

Simply Wall St.
·
Jul 17

Robert W. Baird Remains a Buy on Resmed (RMD)

TIPRANKS
·
Jul 16

Resmed (RMD) was upgraded to a Buy Rating at RBC Capital

TIPRANKS
·
Jul 15

RBC Upgrades ResMed to Outperform From Sector Perform, Adjusts Price Target to $294 From $255

MT Newswires Live
·
Jul 15